Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.

Oncotarget · 2017 · PMC5370046 · PMID 28061451

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The latest results of ETNA trial showed a clinical overall response rate of 69.4% after first 4 cycles of single-agent neoadjuvant nab-paclitaxel, even though the improved pCR rate with nab-paclitaxel did not reach statistical significance [ 39 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.